Key result
Lower serum erythropoietin linked to ~14% higher odds of saphenous vein graft disease.
Why the study?
Is serum erythropoietin level associated with saphenous vein graft disease in patients with prior coronary artery bypass graft surgery?
Cross-Sectional (n=85)
Is serum erythropoietin level associated with saphenous vein graft disease in patients with prior coronary artery bypass graft surgery?
A low serum erythropoietin level is independently associated with saphenous vein graft disease in patients with prior CABG, suggesting a potential pathophysiological role.
Answers are grounded in this paper and cite their sources.
Low erythropoietin levels were associated with saphenous vein graft disease post-CABG; leaves open a modifiable role for erythropoietin in future graft patency trials.
OBJECTIVE: To measure the serum erythropoietin (EPO) level in patients with saphenous vein grafts (SVGs) and to compare the EPO level in those with and without SVG disease. SUBJECTS AND METHODS: The study included 85 consecutive patients with a history of coronary artery bypass graft surgery that underwent elective coronary angiography. Patients with >30% stenosis (diseased grafts) in at least one saphenous graft were included in group 1 (diseased group: n = 40), and group 2 (nondiseased group: n = 45) consisted of patients without diseased SVGs. The EPO level was measured using enzyme-linked immunosorbent assay (ELISA) using a commercially available ELISA kit; x03C7;2 test and independent samples t test were used where appropriate. Logistic regression was used for multivariate analysis. RESULTS: There were not any significant differences in age, gender, or cardiovascular risk factors between the two groups except for increased triglyceride and low high-density lipoprotein levels in group 2. The EPO level was significantly higher in the nondiseased SVG group than in the diseased SVG group (25.5 ± 9.6 vs. 17.8 ± 6.8 mU ml-1, p = 0.002). Multivariate logistic regression analysis showed that the serum EPO level was an independent predictor of SVG disease (OR 1.14, 95% CI 1.06-1.24, p = 0.001). CONCLUSION: In this study, SVG disease was associated with a low serum EPO level, suggesting that a low EPO level could be predictive of and contributes to the pathophysiology of SVG disease.
No takes yet. Share an insight, caveat, or question.
Kocaoğlu et al. (2015) conducted a cross-sectional in Saphenous vein graft disease (n=85). Serum erythropoietin (EPO) level vs. Nondiseased saphenous vein grafts was evaluated on Saphenous vein graft disease (OR 1.14, 95% CI 1.06-1.24, p=0.001). Serum erythropoietin level was an independent predictor of saphenous vein graft disease, with lower levels observed in patients with diseased grafts.
Synapse has enriched 10 related papers. Consider them for comparative context: